2025
Examining psychiatric and cognitive adverse effects of brivaracetam, clobazam, lacosamide, eslicarbazepine, and perampanel in a veteran population
Nuthalapati P, DeBonis D, Gopaul M, Okafor C, Orner M, Jimenez A, Altalib H. Examining psychiatric and cognitive adverse effects of brivaracetam, clobazam, lacosamide, eslicarbazepine, and perampanel in a veteran population. Epilepsy & Behavior 2025, 172: 110557. PMID: 40570732, DOI: 10.1016/j.yebeh.2025.110557.Peer-Reviewed Original ResearchVeteran populationRetrospective analysis of veteransPopulation of veteransAnalysis of veteransICD-10 codesPsychiatric adverse effectsAnti-seizure medicinesVA systemICD-10Neurology noteMale participantsVeteransCognitive adverse effectsSafety analyticsIntegrated programCognitive disordersAdverse effectsORQ1-Q3Treatment initiationChronic neurological disorderExercise cautionEffects of brivaracetamPopulationMedian ageLong term feeding tube use in head and neck cancer survivors – a secondary analysis of patient and treatment related factors
Galloway T, Pugh S, Ridge J, Nguyen-Tan P, Rosenthal D, Gillison M, Garden A, Dunlap N, Caudell J, Jones C, Bauman J, Bahig H, Shenouda G, Currey A, Koyfman S, Stokes W, Read N, Lyness J, Yom S, Le Q. Long term feeding tube use in head and neck cancer survivors – a secondary analysis of patient and treatment related factors. International Journal Of Radiation Oncology • Biology • Physics 2025 PMID: 40473230, DOI: 10.1016/j.ijrobp.2025.05.064.Peer-Reviewed Original ResearchIntensity modulated radiation therapyOropharynx cancer patientsOropharynx cancerFeeding tube useTube useAccelerated fractionationTreatment initiationPredictive factorsFeeding tubeIntensity modulated radiation therapy techniquesTreated with 3DCRTSecondary analysis of patientsT4 tumor stageAnalysis of patientsTreatment related factorsPost hoc secondary analysisTreatment completionYears of smokingSecondary analysisChemoradiation trialsConcurrent chemotherapyMedian followupConcomitant boostConformal radiationRadiation therapyHigh-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma.
Fiala M, Ji M, Slade M, Huber J, Shih Y, Wang M, Colditz G, Wang S, Vij R, Chang S. High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma. JCO Oncology Practice 2025, op2400978. PMID: 40354593, DOI: 10.1200/op-24-00978.Peer-Reviewed Original ResearchStem-cell transplantationMultiple myelomaTreatment initiationHigh-deductible health plan enrollmentHigh-deductible health plansTransplant receiptShorter time to treatment initiationTime to treatment initiationOOP costsHealth Insurance DatabaseAssociated with delayStatistically significant differenceHealth plansPlan enrolleesOut-of-pocket health care costsYounger patientsOut-of-pocket (OOP) costsCox regressionPrimary outcomeMultivariate analysisSecondary outcomesInsurance databasePatientsTotal health careHealth care costsImpact of an electronically‐integrated clinical pathway on hospital initiation of medications for alcohol use disorder and subsequent hospital utilization
Cole K, Weimer M, Wang K, Fiellin D, Advani A, Shah N, Zemaitis C, Rhodes D. Impact of an electronically‐integrated clinical pathway on hospital initiation of medications for alcohol use disorder and subsequent hospital utilization. Journal Of Hospital Medicine 2025 PMID: 40221929, DOI: 10.1002/jhm.70049.Peer-Reviewed Original ResearchClinical pathwayAlcohol use disorderED returnUse disorderHospital-based strategiesAcademic medical centerTertiary academic medical centerDays of dischargeHospital InitiativeInitiation of medicationHealth systemHospital utilizationMultiple barriersIncreased oddsConsecutive adult inpatientsHospital dischargeSecondary outcomesIncreased low ratesAdult inpatientsMedical CenterTreatment initiationHospitalVoluntary useReadmissionMedicationEconomic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride Initiation
Feuerstadt P, Lu M, Terasawa E, Terreri B, Du S, Pi S, Westermeyer B, Ayyagari R, Lembo A, Moshiree B, Boules M, Cash B. Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride Initiation. Gastro Hep Advances 2025, 4: 100664. PMID: 40491438, PMCID: PMC12148438, DOI: 10.1016/j.gastha.2025.100664.Peer-Reviewed Original ResearchChronic idiopathic constipationHealth care resource utilizationHealth care costsCare costsIdiopathic constipationEvaluate health care resource utilizationMedication useStudy periodMedical health care costsMedical costsProportion of patientsIBM MarketScan Commercial ClaimsEconomic burdenEconomic burden of patientsMarketScan Commercial ClaimsIncreased pharmacy costsAssessed 6 monthsBurden of patientsTreatment initiationPrucaloprideAll-CauseOutpatient visitsPrescription fillsPatientsDiagnosis codesObservational pilot using a Data to Care intervention strategy to promote HCV re-engagement and cure for persons with HIV/HCV co-infection who are out of care
Wegener M, Gosselin D, Brooks R, Speers S, Villanueva M. Observational pilot using a Data to Care intervention strategy to promote HCV re-engagement and cure for persons with HIV/HCV co-infection who are out of care. BMC Health Services Research 2025, 25: 140. PMID: 39856760, PMCID: PMC11763122, DOI: 10.1186/s12913-025-12307-6.Peer-Reviewed Original ResearchConceptsDepartment of Public HealthHepatitis C virus treatment initiationHIV/HCV co-infectionHepatitis C virusPublic health strategiesConnecticut Department of Public HealthRe-EngagementMethodsIn partnershipOutreach outcomesCare engagementCo-InfectionHealth strategiesTreatment initiationHIV/HCV co-infected personsHepatitis C virus cureFollow-up approachHepatitis C virus treatmentCo-infected personsDirect-acting antiviralsIntervention strategiesPublic healthOutreach effortsPersons co-infectedHIVObservational pilotFactors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis.
Kim S, Can M, Agizew T, Auld A, Balcells M, Bjerrum S, Dheda K, Dorman S, Esmail A, Fielding K, Garcia-Basteiro A, Hanrahan C, Kebede W, Kohli M, Luetkemeyer A, Mita C, Reeve B, Silva D, Sweeney S, Theron G, Trajman A, Vassall A, Warren J, Yotebieng M, Cohen T, Menzies N. Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis. PLOS Medicine 2025, 22: e1004502. PMID: 39804959, PMCID: PMC11729971, DOI: 10.1371/journal.pmed.1004502.Peer-Reviewed Original ResearchConceptsIndividual Patient Data Meta-AnalysisPatient data meta-analysisTreatment initiationData Meta-AnalysisBacteriological test resultsTB treatmentFactors associated with treatment initiationMultiple factors influence decisionsAssociated with treatment initiationTuberculosis treatment initiationMeta-analysisNegative test resultsPositive test resultsFactors influence decisionsHIV infectionPulmonary tuberculosisSmear microscopyNight sweatsClinical examinationMale sexClinical criteriaHierarchical Bayesian logistic regressionCohort studySystematic reviewTreatment decisionsAutogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Lopez J, Powles T, Braiteh F, Siu L, LoRusso P, Friedman C, Balmanoukian A, Gordon M, Yachnin J, Rottey S, Karydis I, Fisher G, Schmidt M, Schuler M, Sullivan R, Burris H, Galvao V, Henick B, Dirix L, Jaeger D, Ott P, Wong K, Jerusalem G, Schiza A, Fong L, Steeghs N, Leidner R, Rittmeyer A, Laurie S, Gort E, Aljumaily R, Melero I, Sabado R, Rhee I, Mancuso M, Muller L, Fine G, Yadav M, Kim L, Leveque V, Robert A, Darwish M, Qi T, Zhu J, Zhang J, Twomey P, Rao G, Low D, Petry C, Lo A, Schartner J, Delamarre L, Mellman I, Löwer M, Müller F, Derhovanessian E, Cortini A, Manning L, Maurus D, Brachtendorf S, Lörks V, Omokoko T, Godehardt E, Becker D, Hawner C, Wallrapp C, Albrecht C, Kröner C, Tadmor A, Diekmann J, Vormehr M, Jork A, Paruzynski A, Lang M, Blake J, Hennig O, Kuhn A, Sahin U, Türeci Ö, Camidge D. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nature Medicine 2025, 31: 152-164. PMID: 39762422, PMCID: PMC11750724, DOI: 10.1038/s41591-024-03334-7.Peer-Reviewed Original ResearchConceptsCD8+ T cellsAdvanced solid tumorsT cellsSolid tumorsCirculating CD8+ T cellsEfficacy of cancer immunotherapyTumor-infiltrating T cellsStimulate T cell responsesResponse to immunotherapyT cell responsesPreliminary antitumor activityPhase 1 studyPhase 1 trialDose escalationPretreated patientsCancer immunotherapyEvaluation of pharmacokineticsCD4+Tumor lesionsTreatment initiationTumor tissuesAtezolizumabClinical activityDisease characteristicsImmunotherapy
2024
Statistical Methods for Accommodating Immortal Time: A Selective Review and Comparison
Wang J, Peduzzi P, Wininger M, Ma S. Statistical Methods for Accommodating Immortal Time: A Selective Review and Comparison. 2024, 53-92. DOI: 10.1007/978-3-031-65937-9_3.Peer-Reviewed Original ResearchAcute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them
Bidikian A, Bewersdorf J, Kewan T, Stahl M, Zeidan A. Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them. Cancers 2024, 16: 4092. PMID: 39682277, PMCID: PMC11640703, DOI: 10.3390/cancers16234092.Peer-Reviewed Original ResearchAcute promyelocytic leukemiaAdvent of all-trans retinoic acidEarly mortalityLong-term treatment toxicitiesArsenic trioxidePromyelocytic leukemiaClinical practiceIncidence of acute promyelocytic leukemiaRates of remissionLong-term outcomesTreatment of acute promyelocytic leukemiaLong-term survivalComprehensive patient evaluationResource-limited settingsTreatment toxicityAll-Trans Retinoic AcidDelayed DiagnosisPatient demographicsSignificant comorbiditiesTreatment initiationOlder patientsExpert centersClinical trialsTreatment outcomesReal-world settingsReal-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer
Doshi J, Li P, Geng Z, Lei X, Pettit A, Armstrong K, Huntington S, Lin J. Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer. Blood 2024, 144: 786-786. DOI: 10.1182/blood-2024-203410.Peer-Reviewed Original ResearchInsurance typeBlood cancerMedicare patientsCommercial insuranceStep therapyFormulary coverageNationwide sample of patientsPrior authorizationTreatment plan changesDelayed treatment initiationMonths pre-indexOdds of rejectionLonger treatment durationLife-extending therapyReal-world studyOral anticancer medicationsSample of patientsBlood cancer patientsPatient ageClinical characteristicsTreatment initiationReal-world analysisBrand-nameRetrospective analysisPre-indexInequalities in Treatment Utilization Among Older Medicare Beneficiaries with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Induction Therapy
Zeidan A, Xu Y, Kapustyan T, Miu K, Chen C, Kamalakar R, Lin C, Ma E, Montez M, Wu Z, Yee T, Sun H, Rava A, Kim S, Huntington S. Inequalities in Treatment Utilization Among Older Medicare Beneficiaries with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Induction Therapy. Blood 2024, 144: 3795-3795. DOI: 10.1182/blood-2024-200213.Peer-Reviewed Original ResearchTime to treatment initiationND-AMLAssociated with lower oddsAcute myeloid leukemiaAML treatmentVEN-HMACharlson Comorbidity IndexTargeted therapyInduction therapyFemale patientsMyeloid leukemiaTreatment initiationShorter time to treatment initiationTherapy uptakeMedicare beneficiariesNewly diagnosed acute myeloid leukemiaLower oddsOdds ratioHematopoietic stem cell transplantationTime-to-treatment initiationDiagnosed acute myeloid leukemiaIn-hospital survival rateLow-dose chemotherapyClinical performance statusStem cell transplantationMDS-166 Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial
Zeidan A, Platzbecker U, Della Porta M, Santini V, Garcia-Manero G, Li J, Kreitz S, Pozharskaya V, Rose S, Lai Y, Davidárcel D, Fenaux P, Shortt J, Komrokji R. MDS-166 Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s387-s388. DOI: 10.1016/s2152-2650(24)01346-6.Peer-Reviewed Original ResearchEA patientsTransfusion-DependentRBC unitsLuspatercept treatmentRBC-TITransfusion burdenMyelodysplastic syndromeLR-MDSRBC transfusionIntermediate-risk myelodysplastic syndromesEA-treated patientsRBC transfusion independenceBone marrow blastsLowered riskTransfusion independenceMarrow blastsTreatment initiationCumulative medianLuspaterceptEpoetin alfaESA-naivePatients adultsEffective treatmentPatientsInterquartile rangeHealth-seeking behaviour and patient-related factors associated with the time to TB treatment initiation in four African countries: a cross-sectional survey
Sathar F, Charalambous S, Velen K, Fielding K, Rachow A, Ivanova O, Rassool M, Lalashowi J, Owolabi O, Nhassengo P, Chihota V, Evans D. Health-seeking behaviour and patient-related factors associated with the time to TB treatment initiation in four African countries: a cross-sectional survey. BMJ Public Health 2024, 2: e001002. PMID: 40018527, PMCID: PMC11816287, DOI: 10.1136/bmjph-2024-001002.Peer-Reviewed Original ResearchTB treatment initiationCross-sectional surveyTB symptomsPrimary care facilitiesTreatment initiationMedian total delayHealth-seeking behaviorNational TB Control ProgrammeTB treatmentCohort of adultsTB control programmesActive case findingPatient-related factorsHealth facilitiesTB servicesHIV prevalenceCare facilitiesDrug-susceptible pulmonary TBTotal delaySecond-leading causeTime to treatment initiationCase findingCox regression modelsStructured questionnaireInitiation of treatmentCardiovascular Risk Estimation and Stratification Among Individuals with Hypercholesterolemia
Bosco G, Mszar R, Piro S, Sabouret P, Gallo A. Cardiovascular Risk Estimation and Stratification Among Individuals with Hypercholesterolemia. Current Atherosclerosis Reports 2024, 26: 537-548. PMID: 38965183, DOI: 10.1007/s11883-024-01225-3.Peer-Reviewed Original ResearchConceptsPolygenic risk scoresCardiovascular risk stratificationLow-density lipoprotein cholesterolCoronary artery calciumRisk stratificationRisk estimatesRisk scoreCardiovascular risk calculatorsEarly life stagesClinical risk scoreCardiovascular risk estimationNegative risk markersPersonalized treatment strategiesElevated lipid levelsImpact of hypercholesterolemiaCardiovascular risk predictionLife stagesArtery calciumInflammatory markersTreatment initiationLipid parametersReal-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e350-e358.e1. PMID: 39034204, DOI: 10.1016/j.clml.2024.05.023.Peer-Reviewed Original ResearchR/R MCLOverall survivalTreatment patternsRelapsed/refractory mantle cell lymphomaReal-world treatment patternsBruton tyrosine kinase inhibitorCovalent Bruton tyrosine kinase inhibitorMantle cell lymphomaTyrosine kinase inhibitorsDevelopment of novel therapeuticsMCL patientsCell lymphomaThird-lineRetrospective studyTreatment initiationResponse durationAdverse eventsElderly patientsKinase inhibitorsPatient subpopulationsPatientsAll-CauseNovel therapeuticsEconomic burdenSurvivalEnhanced Tuberculosis Diagnosis With Computer-aided Chest X-ray and Urine Lipoarabinomannan in Adults With HIV Admitted to Hospital (CASTLE Study): A Cluster Randomized Trial
Burke R, Nyirenda S, Mtenga T, Twabi H, Joekes E, Walker N, Nyirenda R, Gupta-Wright A, Nliwasa M, Fielding K, MacPherson P, Corbett E. Enhanced Tuberculosis Diagnosis With Computer-aided Chest X-ray and Urine Lipoarabinomannan in Adults With HIV Admitted to Hospital (CASTLE Study): A Cluster Randomized Trial. Clinical Infectious Diseases 2024, 80: 1143-1151. PMID: 38748183, PMCID: PMC12135911, DOI: 10.1093/cid/ciae273.Peer-Reviewed Original ResearchCluster randomised trialTB treatment initiationUsual careChest X-rayPlus usual careUsual care armRandomised trialsTB diagnosisUrine lipoarabinomannanAntiretroviral therapyTreatment initiationDiagnostic armZomba Central HospitalIntention-to-treat analysisTB diagnosticsAdmitted to hospitalModified intention-to-treat analysisCare armCD4 cell countDigital chest X-rayUndiagnosed TBPost-recruitmentCause of deathSecondary outcomesPrimary outcomePredicting response to non-selective beta-blockers with liver–spleen stiffness and heart rate in patients with liver cirrhosis and high-risk varices
Giuffrè M, Dupont J, Visintin A, Masutti F, Monica F, You K, Shung D, Crocè L. Predicting response to non-selective beta-blockers with liver–spleen stiffness and heart rate in patients with liver cirrhosis and high-risk varices. Hepatology International 2024, 19: 460-471. PMID: 38664292, PMCID: PMC12003444, DOI: 10.1007/s12072-024-10649-7.Peer-Reviewed Original ResearchHigh-risk varicesHepatic venous pressure gradientLiver stiffnessLiver cirrhosisSpleen stiffnessVariceal gradeHeart rateCohort of cirrhotic patientsNon-selective beta-blockersPercentual decreaseAssessed therapeutic responseMultivariate modelVenous pressure gradientCut-off valueOptimal cut-offAssociated with better predictionNSBB treatmentPrimary prophylaxisHemorrhagic episodesCirrhotic patientsTherapeutic responseBeta-blockersNSBBTreatment initiationProspective studySecond‐line immunotherapy in new onset refractory status epilepticus
Hanin A, Muscal E, Hirsch L. Second‐line immunotherapy in new onset refractory status epilepticus. Epilepsia 2024, 65: 1203-1223. PMID: 38430119, DOI: 10.1111/epi.17933.Peer-Reviewed Original ResearchFebrile infection-related epilepsy syndromeSecond-line immunotherapyOnset refractory status epilepticusRefractory status epilepticusIntrathecal dexamethasoneStatus epilepticusCytokine levelsFunctional outcomesCerebrospinal fluid cytokine levelsInitiation of anakinraReduction of seizure frequencyLong-term functional outcomeResponse to treatmentSE onsetElevated serumFebrile infectionsImmune dysregulationLong-term disabilityTreatment initiationCase reportCytokine measurementsProspective studyAnakinraImmunotherapyTocilizumabClinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States
Lembo A, Cash B, Lu M, Terasawa E, Terreri B, Du S, Ayyagari R, Feuerstadt P, Moshiree B, Westermeyer B, Pi S, Boules M. Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States. Clinical And Translational Gastroenterology 2024, 15: e00687. PMID: 38357940, PMCID: PMC11124638, DOI: 10.14309/ctg.0000000000000687.Peer-Reviewed Original ResearchConstipation-related symptomsChronic idiopathic constipationProportion of patientsComplications 6 monthsIdiopathic constipationRetrospective cohort analysisDecreased 6 monthsMedicare Supplemental databaseICD-10 procedurePatient ageTreatment initiationClinical outcomesPrucalopride treatmentCohort analysisComplicationsPrucaloprideObservational studyPatientsSupplemental databaseICD-10 Procedure Coding SystemCommercial ClaimsDiagnosis codesICD-10-CMSymptomsClinical Modification
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply